Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T.A. van der Graaf, Peter Hohenberger, Jean‐Yves Blay et al.|The Lancet|2012Cited by 2.1k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Peter Reichardt et al.|The Lancet|2012Cited by 1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Angelo Paolo Dei Tos et al.|The Lancet Oncology|2014Cited by 1.2k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, Sant P. Chawla et al.|The Lancet|2016Cited by 766
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean‐Yves Blay, Margaret von Mehren, César Serrano et al.|The Lancet Oncology|2020Cited by 406